Eklira Genuair, also known by its generic name Aclidinium Bromide, is a long-acting muscarinic antagonist (LAMA) used in the management of chronic obstructive pulmonary disease (COPD). It works by relaxing the muscles around the airways in the lungs, which helps to ease symptoms such as shortness of breath, wheezing, and coughing, thereby improving breathing in individuals with COPD. Eklira Genuair is administered through a dry powder inhaler called Genuair, designed for oral inhalation, providing a convenient method of delivery directly to the lungs. It is typically prescribed as a maintenance treatment for COPD and is not intended for the relief of acute bronchospasm or for the treatment of asthma. Patients are advised to use Eklira Genuair regularly to achieve the best possible effect in managing their condition.